prikaz prve stranice dokumenta Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study
Access restricted to students and staff of home institution
Scientific paper - Original scientific paper
Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study
Diabetes Research and Clinical Practice, 177 (2021); 108884. https://doi.org/10.1016/j.diabres.2021.108884
Mikolasevic, I.; Rahelic, D.; Turk-Wensween, T.; Ruzic, A.; Domislovic, V.; Hauser, G.; Matic, T.; Radic-Kristo, D.; Krznaric, Z.; Radic, M.; Filipec Kanizaj, T.; Martinovic, M.; Jerkic, H.; Medjimurec, M.; Targher, G. More authors...

Cite this document

Mikolasevic, I., Rahelic, D., Turk Wensween, T., Ruzic, A., Domislovic, V., Hauser, G. ... Targher, G. (2021). Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study. Diabetes Research and Clinical Practice, 177., 108884. doi: 10.1016/j.diabres.2021.108884

Mikolasevic, I., et al. "Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study." Diabetes Research and Clinical Practice, vol. 177, 2021, p. 108884. https://doi.org/10.1016/j.diabres.2021.108884

Mikolasevic, I., D. Rahelic, T. Turk Wensween, A. Ruzic, V. Domislovic, G. Hauser, T. Matic, et al. "Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study." Diabetes Research and Clinical Practice 177 (2021): 108884. https://doi.org/10.1016/j.diabres.2021.108884

Mikolasevic, I., et al. (2021) 'Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study', Diabetes Research and Clinical Practice, 177, p. 108884. doi: 10.1016/j.diabres.2021.108884

Mikolasevic I, Rahelic D, Turk Wensween T, Ruzic A, Domislovic V, Hauser G, and sur.. Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study. Diabetes Research and Clinical Practice [Internet]. 2021 July [cited 2024 December 15];177:108884. doi: 10.1016/j.diabres.2021.108884

I. Mikolasevic, et al., "Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study", Diabetes Research and Clinical Practice, vol. 177, p. 108884, July 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:264:519541. [Accessed: 15 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study
AuthorI. Mikolasevic
AuthorD. Rahelic
AuthorT. Turk-Wensween
AuthorA. Ruzic
AuthorV. Domislovic
AuthorG. Hauser
AuthorT. Matic
AuthorD. Radic-Kristo
AuthorZ. Krznaric
AuthorM. Radic
AuthorT. Filipec Kanizaj
MBZ: 272175
AuthorM. Martinovic
AuthorH. Jerkic
AuthorM. Medjimurec
AuthorG. Targher
Author's institution(Merkur University Hospital)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
AimsThe aim of this study was to investigate whether controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), as assessed by vibration-controlled transient elastography (VCTE), are associated with chronic vascular complications of diabetes mellitus type 2 (T2DM). Methods We studied 442 outpatients with established T2DM, and who underwent VCTE and extensive assessment of chronic vascular complications of diabetes. ResultsA quarter of analyzed patients had a previous history of myocardial infarction and/or ischemic stroke, and about half of them had at least one microvascular complication (chronic kidney disease (CKD), retinopathy or polyneuropathy). The prevalence of liver steatosis (i.e., CAP ≥ 238 dB/m) and significant liver fibrosis (i.e., LSM ≥ 7.0/6.2 kPa) was 84.2% and 46.6%, respectively. Significant liver fibrosis was associated with an increased likelihood of having myocardial infarction (adjusted-odds ratio 6.61, 95%CI 1.66–37.4), peripheral polyneuropathy (adjusted-OR 4.55, 95%CI 1.25–16.6), CKD (adjusted-OR 4.54, 95%CI 1.24–16.6) or retinopathy (adjusted-OR 1.81, 95%CI 1.62–1.97), independently of cardiometabolic risk factors, diabetes-related variables, and other potential confounders. Liver steatosis was not independently associated with any macro-/microvascular diabetic complications. ConclusionsSignificant liver fibrosis is strongly associated with the presence of macro-/microvascular complications in patients with T2DM. These results offer a new perspective on the follow-up of people with T2DM.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleDiabetes Research and Clinical Practice
Numberingvol. 177, p. 108884
p-ISSN0168-8227
DOIhttps://doi.org/10.1016/j.diabres.2021.108884
URN:NBNurn:nbn:hr:264:519541
Publication2021-07
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S0168822721002448
Type of resourceText
Access conditionsInstitutional access
Terms of useLicence In copyright icon
Created on2024-12-06 09:10:35